Amphastar Pharmaceuticals, Inc. Accounts Payable
Amphastar Pharmaceuticals, Inc. (AMPH) had Accounts Payable of $28.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $28.93M.
- 2026-03-31: Accounts Payable, Current $35.50M.
- 2025-12-31: Accounts Payable, Current $32.59M.
- 2025-09-30: Accounts Payable, Current $40.54M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $28.93M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $35.50M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $32.59M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $40.54M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $41.88M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $52.81M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $30.51M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $34.09M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $31.77M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $36.53M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $25.44M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $31.97M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $18.83M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $21.98M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $20.50M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $19.96M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $31.07M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $23.84M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $22.21M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $21.66M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $27.75M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $22.99M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $24.36M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $23.17M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $21.71M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $16.51M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $25.06M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $22.04M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $31.46M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $34.27M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $31.32M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $22.67M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $21.66M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $15.63M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $16.63M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $9.59M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $14.91M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $19.30M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $19.93M 10-K · filed 2018-03-14 | $16.20M 10-K · filed 2017-03-15 |
| 2016-09-30 | $13.44M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $18.77M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $18.62M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $13.87M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $12.27M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $18.45M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $18.95M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $10.16M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $10.01M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $17.76M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | $20.38M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |